0000895051 false 0000895051 2020-08-27 2020-08-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 27, 2020

 

CASI PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

  

delaware

(State or other jurisdiction  of

incorporation or organization)

0-20713

(Commission File Number)

 

58-1959440

(IRS Employer Identification

No.)

 

9620 Medical Center Drive, Suite 300

Rockville, Maryland

(Address of principal executive offices)

 

20850

(Zip Code)

 

(240) 864-2600

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock   CASI   Nasdaq Capital Market

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

  Item 8.01 Other Events

   

On August 27, 2020, CASI Pharmaceuticals (WUXI) Co., Ltd. (“CASI-Wuxi”), a joint venture between CASI Pharmaceuticals, Inc. (the “Company”) and Wuxi Jintou Huicun Investment Enterprise (Limited Partnership) in which the Company owns 80% of the equity interests, entered into the Construction Project Contract (the “Construction Contract”) with China Electronic System Engineering No. 2 Construction Co., Ltd. (“China Engineering”). Pursuant to the Construction Contract, CASI-Wuxi will pay a contract price of RMB 74,588,310 (equivalent to USD $10,923,408) to retain China Engineering to complete the phase 1 project of CASI-Wuxi’s research and development production base, consisting of construction and installation of a combined factory building, warehouse, guard house and public works. The estimated completion date is October 13, 2023.

      

Item 9.01Financial Statements and Exhibits.

 

(d)     Exhibits

 

Exhibit No. Description of Document
   
104 Inline XBRL for the cover page of this Current Report on Form 8-K

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  CASI PHARMACEUTICALS, INC. 
   
 

/s/ Larry Zhang

 

Larry Zhang

President

  

Date: September 2, 2020

 

 

 

 

v3.20.2
Cover
Aug. 27, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 27, 2020
Entity File Number 0-20713
Entity Registrant Name CASI PHARMACEUTICALS, INC.
Entity Central Index Key 0000895051
Entity Tax Identification Number 58-1959440
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 9620 Medical Center Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 240
Local Phone Number 864-2600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol CASI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false